Literature DB >> 9081105

Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study.

M Ernofsson1, S Thelin, A Siegbahn.   

Abstract

OBJECTIVES: Cardiopulmonary bypass is associated with extensive thrombin generation and cell activation. Our main hypothesis in this study was that the expression of tissue factor on circulating monocytes contributes to the formation of thrombin.
METHODS: Markers of activation of the coagulation cascade and cell activation were measured in 26 patients undergoing elective heart operations randomized to the use of heparin-coated (Duraflo II, n = 13) or standard cardiopulmonary bypass circuits (n = 13).
RESULTS: Thrombin generation, measured as the thrombin-antithrombin complex, increased considerably during cardiopulmonary bypass with peak levels 3 hours afterward and with remaining elevation 20 hours later. Despite increased monocyte and granulocyte activation and increased levels of monocyte chemotactic protein-1, which upregulates monocyte tissue factor expression in vitro, monocyte tissue factor expression was not increased at the end of cardiopulmonary bypass. Furthermore, at this time the monocytes were less sensitive to in vitro stimulation by endotoxin. These results might be explained by simultaneous enhanced levels of interleukin-10, which effectively downregulates monocyte tissue factor expression in vitro. Twenty hours after cardiopulmonary bypass was discontinued, the tissue factor expression on freshly isolated monocytes and on monocytes stimulated by endotoxin was significantly increased compared with preoperative levels. At this time increased activation markers of granulocytes, monocytes, and lymphocytes were also recorded. None of the measured parameters was found to be different between the groups.
CONCLUSIONS: The tissue factor expression on circulating monocytes is upregulated the day after heart operations. The clinical relevance and the regulatory mechanism behind the enhanced expression, however, are not fully elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9081105     DOI: 10.1016/S0022-5223(97)70373-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

Review 2.  Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.

Authors:  Maryam Yavari; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-01-23       Impact factor: 2.300

3.  Recombinant factor VII is associated with worse survival in complex cardiac surgical patients.

Authors:  Andrej Alfirevic; Andra Duncan; Jing You; Cheryl Lober; Edward Soltesz
Journal:  Ann Thorac Surg       Date:  2014-06-24       Impact factor: 4.330

4.  [Tissue factors and venous thromboembolism in cancer patients].

Authors:  Huiqi Zhu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-25

5.  The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection -A case report-.

Authors:  Wook Jong Kim; Jin-Young Oh; Hyo Jung Son; Ji-Hyun Chin; Dae-Kee Choi; Eun Ho Lee; Ji-Yeon Sim; In-Cheol Choi
Journal:  Korean J Anesthesiol       Date:  2011-11-23

6.  Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity.

Authors:  Ruth Heying; Wim van Oeveren; Stefanie Wilhelm; Katharina Schumacher; Ralph G Grabitz; Bruno J Messmer; Marie-Christine Seghaye
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Platelets protect lung from injury induced by systemic inflammatory response.

Authors:  Shuhua Luo; Yabo Wang; Qi An; Hao Chen; Junfei Zhao; Jie Zhang; Wentong Meng; Lei Du
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

8.  Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations.

Authors:  Wen Yan; Chengluan Xuan; Guojia Ma; Liang Zhang; Ning Dong; Zijian Wang; Rihao Xu
Journal:  J Cardiothorac Surg       Date:  2014-09-02       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.